Fatal pulmonary complication during induction therapy in a patient with ANCA-associated vasculitis

Brigita Jonaitytė¹, Rūta Kibarskytė¹, Edvardas Danila²,³, Marius Miglinas¹,⁴, Dmitrij Šeinin⁵, Rokas Stulpinas⁵, Jurgita Mitrikevičienė¹,⁴, Vygantas Gruslys²,³, Virginija Šileikienė²,³, Rolandas Zablockis²,³

¹ Faculty of Medicine of Vilnius University, Vilnius, Lithuania
² Clinic of Infectious and Chest Diseases, Dermatovenereology and Allergology of Vilnius University
³ Center of Pulmonology and Allergology of Vilnius University Hospital Santariskių Klinikos
⁴ Nephrology Center of Vilnius University Hospital Santariskių Klinikos
⁵ National Center of Pathology, Affiliate of Vilnius University Hospital Santariskiu Clinics (Santariskiu Clinics)

ANCA-associated vasculitis (AAV) is an inflammatory systemic disorder affecting small to medium sized vessels and likely leading to any organ dysfunction. Adequate treatment is important to avoid mortality or severe organ damage. In most cases initial treatment (induction therapy) allows to achieve remission. Induction therapy leads to immunosuppression and may cause severe infections. However, in vasculitis patients even an intensive immunosuppressive therapy is rarely complicated by an invasive fungal infection.

We present a case in a 29-year old male patient with newly diagnosed AAV. He suffered a fatal pulmonary complication of the induction immunosuppressive treatment. Pathological (infectious) changes in the lungs were misinterpreted as progression of the vasculitis and he died due to disseminated angioinvasive aspergillosis. A clinical course, imaging and histopathology of this case are described and discussed.

Keywords: ANCA-associated vasculitis, immunosuppressive therapy, invasive aspergillosis
INTRODUCTION

The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an inflammatory systemic disorder characterized by the production of ANCA (1). Immunosuppressive agents are the mainstay of treatment, divided into a remission induction and a maintenance therapy. Glucocorticoids with cyclophosphamide remain the standard care in consensus guidelines for the treatment of generalised disease. However, even with the best available therapy, relapse rates remain unacceptably high and treatment-related morbidity and mortality remain high as well (2–4).

Both vasculitis itself and complications of induction therapy may cause death (5). However, in vasculitis patients even an intensive immunosuppressive therapy is rarely complicated by an invasive fungal infection (6). In this article we present a case of AAV resulting in death, due to angioinvasive pulmonary Aspergillus infection.

CASE REPORT

A 29-year old male patient was admitted to the hospital with complaints of a cough, urine discoloration and a decreased urine output. On clinical examination, the patient presented afebrile, with a blood pressure of 170/80 mmHg and a heart rate of 80 bpm. Bilateral moist rales were observed on lung auscultation. During the examination, the patient coughed up blood for the first time. Laboratory studies demonstrated leukocytosis (12.7 × 10⁹/L), eosinophilia (2.1 × 10⁹/L), high ratio of the erythrocyte sedimentation rate (66 mm/h), plasma C-reactive protein (30 mg/L) and myoglobin (505 µg/L). His creatinine (238 µmol/L) and urea (12 mmol/L) levels were markedly elevated. The urine analysis showed proteinuria and hematuria. Tests for blood, urine cultures, and infectious diseases (tuberculosis, hepatitis B and C, HIV) were all negative. An abdomen ultrasound revealed diffuse changes of the renal parenchyma. An initial chest X-ray showed polysegmental infiltration in both lungs, which resolved after treatment with amoxicillin/clavulanic acid.

Considering a systematic disease, an autoantibody analysis was obtained and a test for ANCA (c-ANCA pattern) was positive. A kidney biopsy was consistent with an active ANCA-associated crescentic focal necrotizing glomerulonephritis without immunoreactive deposits (Fig. 1). During the first week of hospitalization the patient’s renal function decreased rapidly (urea 36 mmol/L and creatinine 807 µmol/L). A treatment with high-dose glucocorticoids and intravenous cyclophosphamide (500 mg/m²) was initiated.

After the initial treatment, the patients’ diuresis increased, urea and creatinine levels were relatively diminished (27 and 330 µmol/L). A second course of treatment was assigned due to the persisting renal dysfunction.

On the 35th day of hospitalization (6 days after the second course of treatment was initiated) a control chest X-ray (Fig. 2) and a subsequent chest CT (Fig. 3) showed a new focal infiltration in the upper lobe of the left lung and a pleural effusion.

Fig. 1. Kidney biopsy. Up to 45% of visible glomeruli reveal cellular crescents (white arrows). Periodic acid–Schiff stain, 200x

Fig. 2. Chest X-ray image. Local infiltration in the upper lobe of the left lung (white arrow)
Testing for D-dimer (1445 µg/L, upper normal limit 250 µg/L) and discovering an acute thrombosis of the right cephalic vein during the Doppler ultrasound examination led to the diagnosis of acute pulmonary artery embolism and a pulmonary infarction. Treatment with oral anticoagulants was initiated. A biopsy to evaluate for a possible vascular pathology in the lungs was not performed due to the patients’ severe condition.

23 days after the second course of cyclophosphamide and a high-dose glucocorticoids treatment, the patient started to complain of a pain on the site of the left scapula, a fatigue and hemoptysis. The chest X-ray (Fig. 4) and CT (Fig. 5) revealed a solid structure and a thick wall pulmonary cavity in the right lung, multiple cavities and a consolidation in the left lung.

Those findings of pulmonary tissue destruction were interpreted as a progression of a vascular pathology process.

Prior to the third course of the treatment an infectious complication of immunosuppressive therapy was suspected. The patient was treated with imipenem/cilastatin and vancomycin. A fibrobronchoscopy with bronchoalveolar lavage (BAL) was performed to exclude the possibility of a fungal infection and tuberculosis. The smears and cultures for *Mycobacterium tuberculosis*, *Pneumocystis jirovecii* and fungi were negative. Unfortunately, the galactomannan level was not evaluated. However, the treatment with fluconasol was initiated. ANCA titer diminished to normal. During the week after the initiation of the third course of therapy, the patient developed multiple...
pneumothoraces, his respiratory and renal dysfunction worsened. The patient died 4 days later.

The autopsy report disclosed AAV with renal and pulmonary impairment as the main cause of death. The presence of vasculitis was also noticed in the coronary arteries. The complications included disseminated angioinvasive *Aspergillus* fungal infection (bilateral fungal pneumonia (Fig. 6), abscesses in the lower lobes of both lungs, an abscess localized in the head of the pancreas and parapancreatic tissue).

**DISCUSSION**

Even in patients with known vasculitis it is challenging to differentiate between a progression of the disease, a complication of a drug therapy, an underlying infection or a combination of these conditions due to their similar presentation (6). In our case respiratory and renal systems were involved. ANCA titers have been shown to correlate highly with disease activity. C-ANCA is associated with GPA with 90–95% sensitivity and 90% specificity in generalized disease. In our case one of the most important findings that led to an AAV diagnosis was a positive test for ANCA titers (c-ANCA pattern).

CT scanning is the most sensitive for the detection of lung involvement in AAV. Nodules and masses are seen in up to 90% of patients: they are usually multiple and bilateral. They also seem to have a tendency towards cavitation. These findings while being non-specific are useful for characterization of the disease manifestations (7, 8). In our case infiltrations were seen in the initial CT scan.

Unfortunately, the pulmonary tissue destruction was interpreted as a progression of this vascular pathology process. Although we were not able to confirm the etiology of the ongoing process in the lungs due to the lack of the lung biopsy, a course of treatment had to be initiated right away because of the patient’s renal function decreased rapidly.

Cyclophosphamide and glucocorticoids are consistently recommended as the ‘standard of care’ for AAV. Clinical deterioration under immunosuppressive treatment should raise a suspicion of an infection, treatment resistance or a relapse of the disease. The autopsy of our patient revealed an invasive pulmonary aspergillosis (IPA). Many authors state that diagnosing IPA is difficult due to the low specificity and sensitivity of the clinical signs, radiologic changes microscopy and cultures of the BAL fluid (8, 9–13).

In our case, a fibrobronchoscopy with BAL were performed, but the culture and direct microscopy for fungi were negative. The reported sensitivity of a direct microscopy is variable from 0 to 90% (9). Microscopic examination should not be considered as an early diagnostic technique (14). It is also known that culture of the fluid collected during BAL typically has a low sensitivity and specificity, especially during the early stages of the disease (8, 10, 11).

Recent studies of the efficacy of serum galactomannan (GM) to diagnose invasive aspergillosis suggest that assays sensitivity varies from 13 to 88% while the specificity ranges from 21 to 100% (9). In non-neutropenic patients with aspergillosis the sensitivity of serum GM detection is not greater than 50%. This limits the use of the method as a diagnostic technique (12). Detection of fungal markers in the BAL fluid has a higher sensitivity and specificity (10).

Although there is debate about the expediency of antifungal prophylaxis even in high-risk patients, prophylactic strategies may be useful for patients who are at a high risk for invasive aspergillosis, but the selection of this specific group remains challenging. Voriconazole is recommended for the primary treatment of IPA in most patients (6).

In conclusion, our report shows that fatal angio-invasive pulmonary *Aspergillus* infection may occur during induction therapy in vasculitis patients.

In case of a discrepancy between the improvement of the kidney symptoms and a deterioration of the pulmonary state during an immunosuppressive therapy, an invasive aspergillosis has to be suspected, and an appropriate testing (including microbiological and serological tests of the blood and BAL fluid) and antifungal therapy should be initiated.

**References**

1. Langford C. Clinical features and diagnosis of small-vessel vasculitis. Clev Clin J Med. 2012; 79 Suppl 3: 3–7.
2. Hamour S, Salama AD, Pusey CD. Management of ANCA-associated vasculitis: current trends and
future prospects. Ther Clin Risk Manag. 2010; 6: 253–64.
3. Smith RM, Jones RB, Jayne DRW. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther. 2012; 14: 210.
4. Yunt ZX, Frankel SK, Brown KK. Diagnosis and management of pulmonary vasculitis. Ther Adv Respir Dis. 2012; 6: 375–90.
5. Tarzi RM, Pusey CD. Current and future prospects in the management of granulomatosis with polyangiitis (Wegener’s granulomatosis). Ther Clin Risk Manag. 2014; 10: 279–93.
6. Segal BH. Aspergillosis. N Eng J Med. 2009; 360: 1870–84.
7. Castaner E, Alguersuari A, Gallardo X, Andreu M, Pallardo Y, Mata JM, Ramirez J. When to suspect pulmonary vasculitis: radiologic and clinical clues. Radiographics. 2010; 30: 33–53.
8. Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012; 186: 56–64.
9. Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica. 2013: 459405.
10. Bergeron A, Belle A, Sulahian A, Lacroix C, Chevret S, Raffoux E, et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest. 2010; 137: 410–5.
11. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev. 2002; 15: 465–84.
12. Torelli R, Sanguinetti M, Moody A, Pagano L, Caira M, De Carolis E, et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol. 2011; 49: 4273–8.
13. Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest. 2010; 138: 817–24.
14. Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Račil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother. 2011; 66 Suppl 1: i15–24.

Brigita Jonaitėtė, Rūta Kibarskytė, Edvardas Danila, Marius Miglinas, Dmitrij Šeinin, Rokas Stulpinas, Jurgita Mitrikevičienė, Vyngantas Gruslys, Virginija Šileikienė, Rolandas Zablockis

MIRTINOS KOMPLIKACIJOS SKIRIANT REMISIJĄ INDUKUOJANTĮ GYDYMĄ SERGANTIEMS ANCA-ASOCIUOTU VASKULITU

Santrauka
ANCA-asocijuotas vaskulitas yra sisteminė uždegiminė liga, kuria sergant pažeidžiamos ne tik plaučių, bet ir kitų organų mažosios bei vidutinio dydžio kraujagyslės. Remisiją indukuojančios terapijos tikslas – kiek įmanoma greičiau sumažinti uždegimą ir ligos simptomus, išvengti negrižtamai audinių pažeidimo. Skiriamas imunosupresinis gydymas gali sukelti infekcinės komplikacijas, iš kurių rečiausiai ir sunkiausiai – invazinė grybelių infekcija.

Straipsnyje pristatome 29 metų amžiaus vyro, kuri amžiaus ANCA-asocijuotas vaskulitas, klinininkų atvejį. Klinininkų pokyčiai plaučiuose buvo traktuoti kaip vaskulito progresija, tačiau skiriant remisiją indukuojantį gydymą ligoniui išsivystė sunkiai inžinės aspergiliozės forma, todėl ji mirė. Straipsnyje aprašoma ligos eiga, pristatomi radiologinių ir histologinių tyrimų vaizdai, aptariamas gydymas ir pateikiami literatūros apžvalgos.

Raktažodžiai: ANCA-asocijuotas vaskulitas, imunosupresinis gydymas, invazinė aspergiliozė